Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
A number of other brokerages have also recently issued reports on AMPH. Piper Sandler raised their price objective on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research note on Wednesday, August 9th. Jefferies Financial Group assumed coverage on Amphastar Pharmaceuticals in a research report on Tuesday, July 25th. They issued a “buy” rating and a $70.00 price target on the stock.
Read Our Latest Stock Analysis on AMPH
Amphastar Pharmaceuticals Stock Performance
Shares of NASDAQ:AMPH opened at $54.51 on Thursday. The stock has a market capitalization of $2.63 billion, a P/E ratio of 27.95 and a beta of 0.82. The company has a current ratio of 1.53, a quick ratio of 1.11 and a debt-to-equity ratio of 0.83. Amphastar Pharmaceuticals has a 1-year low of $26.76 and a 1-year high of $67.66. The business has a 50-day moving average price of $57.73 and a two-hundred day moving average price of $45.39.
Insider Buying and Selling
In related news, EVP Rong Zhou sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $48.24, for a total transaction of $241,200.00. Following the completion of the transaction, the executive vice president now owns 88,313 shares in the company, valued at $4,260,219.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 5,000 shares of the business’s stock in a transaction dated Tuesday, June 13th. The stock was sold at an average price of $48.24, for a total value of $241,200.00. Following the completion of the transaction, the executive vice president now directly owns 88,313 shares of the company’s stock, valued at $4,260,219.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 11,000 shares of the stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $46.35, for a total value of $509,850.00. Following the completion of the sale, the chief financial officer now owns 105,603 shares of the company’s stock, valued at $4,894,699.05. The disclosure for this sale can be found here. Insiders have sold 89,306 shares of company stock valued at $4,470,696 in the last 90 days. 27.80% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of AMPH. BlackRock Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 1.1% during the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock worth $200,854,000 after acquiring an additional 75,616 shares during the period. Federated Hermes Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 0.7% in the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock valued at $125,199,000 after purchasing an additional 23,095 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Amphastar Pharmaceuticals by 1.8% during the third quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock worth $73,234,000 after buying an additional 45,385 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 0.7% during the second quarter. Dimensional Fund Advisors LP now owns 1,930,615 shares of the company’s stock worth $110,948,000 after buying an additional 13,044 shares in the last quarter. Finally, State Street Corp raised its position in Amphastar Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 1,540,846 shares of the company’s stock valued at $53,606,000 after buying an additional 218,895 shares during the last quarter. Institutional investors own 62.49% of the company’s stock.
About Amphastar Pharmaceuticals
(Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amphastar Pharmaceuticals wasn’t on the list.
While Amphastar Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report